Results 1 to 10 of about 5,550 (180)
Frequency and characteristics of the V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis [PDF]
Journal of International Medical Research, 2020 Objective To analyse the frequency and characteristics of the Janus kinase 2 ( JAK2) V617F mutation in patients with cerebral venous sinus thrombosis (CVST) with thrombocytosis.
Qiang Ma
doaj +2 more sources
JAK2-V617F mutation among blood donors: A meta-analysis. [PDF]
Saudi Med JTo systematically review evidence on the prevalence of the JAK2V617F (JAK2) mutation and polycythemia vera (PV) among all blood donors, focusing on those with elevated hematocrit. Although blood donors are generally healthy, considering a preclinical stage of myeloproliferative neoplasm, especially in those with polycythemia, is crucial.
Alsharif MH +3 more
europepmc +3 more sources
JAK2 V617F MUTATION SCANNING IN PATIENTS WITH ADRENAL INCIDENTALOMA. [PDF]
Acta Endocrinol (Buchar), 2017 Adrenal incidentaloma are lesions which are stated incidentally by imaging methods when there is no suspicion of any disease in adrenal gland. Inappropriate Jak2 signaling causes some solid and hematological malignancies. But the Jak2 mutation has not been previously evaluated with regard to adrenal tumors.
Ekinci F +5 more
europepmc +5 more sources
Determination of the JAK2 V617F mutation in thrombosis patients
Journal of Associated Medical Sciences, 2023 Background: Janus kinase 2 (JAK2) gene mutation causes uncontrolled myeloproliferation independent of cytokines and abnormal formation of the endogenous erythroid colony.
Sutada Magmuang +7 more
doaj +2 more sources
The JAK2 V617F mutation in isolated neutropenia. [PDF]
EXCLI J, 2018 EXCLI Journal; 17:Doc1; ISSN 1611 ...
Langabeer SE.
europepmc +4 more sources
4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status [PDF]
Thrombosis JournalEssential thrombocythemia (ET) is a kind of myeloproliferative neoplasms. Thrombosis is one of the common symptoms, however, the incidence of thrombosis in ET with JAK2, CALR, MPL gene mutations varies greatly, and the underlying mechanism is unclear ...
Xueya Zhang, Xizhe Guo
doaj +2 more sources
Hematology, 2022 Background: The V617F mutation of Janus-associated kinase 2 (JAK2) is common in myeloproliferative neoplasms (MPN). JAK2 V617F mutation can be detected in patients with de novo acute myeloid leukemia (AML), but de novo acute promyelocytic leukemia (APL ...
Yi-zhi Jiang +8 more
doaj +1 more source
Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. [PDF]
PLoS ONE, 2013 BACKGROUND: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation.
Juan Zhou +9 more
doaj +1 more source
DIAGNOSTIC VALUE OF JAK2 V617F MUTATIONAL SCREENING IN PATIENTS WITH BUDD-CHIARI SYNDROME [PDF]
Ain Shams Medical Journal, 2019 Background: The diagnosis of underlying myeloproliferative neoplasms (MPNs) is often problematic in patients with Budd Chiari syndrome (BCS). A clonal mutation in JAK2 tyrosine kinase (JAK2V617F) occurs in a high proportion of patients with MPNs and is ...
Esraa A +3 more
doaj +1 more source
Pakistan Journal of Pharmaceutical Sciences, 2021 Chronic Myeloid Leukaemia (CML) is characterized by BCR-ABL1 mutation. A number of research studies have published reports of concomitant JAK2-V617F mutation in BCR-ABL positive Chronic Myeloid Leukaemia.
Nasir Ahmad +6 more
doaj +1 more source